Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011892 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
NCT03011892 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 307 participants.
The verdict
NCT03011892, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
Interventions
- DRUG Ruxolitinib 0.15% Cream QD
- DRUG Ruxolitinib 0.5% Cream QD
- DRUG Ruxolitinib 1.5% Cream QD
- DRUG Ruxolitinib 1.5% Cream BID
- DRUG Triamcinolone 0.1% Cream BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2017-01-09 |
| Est. Completion | 2018-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03011892
The ClinicalTrials.gov registry entry for NCT03011892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ruxolitinib 0.15% Cream QD is the first listed.
NCT03011892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03011892 about?
NCT03011892 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis". The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
What is the current status of trial NCT03011892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2017-01-09. Estimated completion is 2018-03-12.
What interventions are being tested in trial NCT03011892?
The interventions under investigation include: Ruxolitinib 0.15% Cream QD (DRUG), Ruxolitinib 0.5% Cream QD (DRUG), Ruxolitinib 1.5% Cream QD (DRUG), Ruxolitinib 1.5% Cream BID (DRUG), Triamcinolone 0.1% Cream BID (DRUG).
Who is sponsoring clinical trial NCT03011892?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.